Why melanoma trial monitoring matters
Melanoma has been the proving ground for immuno-oncology since the approval of ipilimumab in 2011. The therapeutic landscape continues to evolve rapidly, with new checkpoint inhibitor combinations, cell therapies, and targeted agents entering clinical development at an accelerating pace.
The volume of active melanoma trials on ClinicalTrials.gov (the live count is on this page) makes the monitoring challenge significant for pharma BD teams, biotech investors, and dermatologic oncology researchers. Key signals to track:
- Novel checkpoint inhibitor combinations (anti-LAG-3, anti-TIGIT, anti-TIM-3 paired with PD-1)
- TIL (tumor-infiltrating lymphocyte) therapy programs following lifileucel approval
- Neoadjuvant/adjuvant immunotherapy trials, a rapidly growing area
- BRAF/MEK inhibitor next-generation combinations
- mRNA-based personalized cancer vaccines (e.g., mRNA-4157/V940 and competitors)
- Trials in uveal melanoma, mucosal melanoma, and acral melanoma, underserved subtypes with distinct biology
Get daily melanoma trial digest
Set your profile once. Receive a clean digest every morning with new trials and updates matching your criteria.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®)… NCT04198766 | Primary completion moved at least 6 years 8 months later Primary endpoint added | Recruiting |
47 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants… NCT06521567 | Oct 13, 2026 · Estimated | Phase 1/2 |
58 more on the Completions page. See the calendar →
What we monitor for melanoma
Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a melanoma watch profile, you can configure:
- Condition keywords: "melanoma", "metastatic melanoma", "uveal melanoma", "mucosal melanoma", "BRAF V600E", "BRAF mutant melanoma"
- Phase filter: Phase 1 only, Phase 2/3, or all phases
- Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
- Status filter: Recruiting only, all active studies, or any status
The melanoma treatment landscape in 2026
Next-generation immunotherapy combinations
The success of nivolumab + relatlimab (Opdualag) validated the dual checkpoint approach in melanoma. Now, dozens of programs are testing combinations involving LAG-3, TIGIT, TIM-3, and other immune checkpoints. Tracking new combination trials gives competitive intelligence teams early visibility into which targets and combinations are being prioritized by pharma companies.
Cell therapy beyond CAR-T
TIL therapy, using a patient's own tumor-infiltrating lymphocytes, has emerged as a distinct cell therapy modality in solid tumors. Following the approval of lifileucel (Amtagvi), multiple competitors are developing next-generation TIL products with shorter manufacturing times, enhanced potency, and combination approaches.
Personalized cancer vaccines
mRNA-based neoantigen vaccines represent one of the most anticipated advances in melanoma. The mRNA-4157/V940 + pembrolizumab combination has generated significant interest, and competitor programs are rapidly entering clinical development. Monitoring vaccine trial starts is essential for companies positioning in this space.
Neoadjuvant immunotherapy
Pre-surgical immunotherapy has shown remarkable pathological complete response rates in resectable melanoma. This paradigm shift is driving a wave of neoadjuvant trial registrations that could reshape the treatment algorithm for early-stage disease.
Who uses melanoma trial monitoring
Pharma and biotech companies
Companies with immuno-oncology programs track melanoma trial activity across the industry. Melanoma is often the first indication for novel immunotherapy mechanisms, making it a bellwether for broader I-O strategy decisions.
Oncology-focused investors
Investors monitor melanoma trial registrations as early signals for immunotherapy platform value. A new Phase 2 combination trial can signal a company's clinical development strategy months before any public announcement.
Academic researchers
Melanoma researchers at academic medical centers track new trial registrations to identify collaboration opportunities, understand the competitive landscape for their own investigator-initiated trials, and stay current on emerging mechanisms.
Frequently asked questions
How current is the melanoma trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track melanoma subtypes separately?
Yes. On Pro ($49/month, or $490/year), you can create up to 10 sponsor and 10 disease watchlists. You might have one profile for uveal melanoma, another for BRAF-mutant trials, and another for all Phase 3 immunotherapy combinations.
Does this cover international melanoma trials?
ClinicalTrials.gov includes trials conducted internationally, so yes, international melanoma trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide, particularly those with US sites.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Melanoma trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
797 active trials, 431 recruiting.
Industry sponsors run 231 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 156.
| Top industry sponsor | Active trials |
|---|---|
| Bristol-Myers Squibb | 8 |
| Merck (MSD) | 6 |
| Novartis Pharmaceuticals | 6 |
| Regeneron Pharmaceuticals | 6 |
| IDEAYA Biosciences | 5 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma NCT03757689 | Active, Not Recruiting | Primary completion pushed from Dec 1, 2024 to Nov 13, 2025 | 2026-10-10 |
| Statins and prOgression of Coronary atheRosclerosis in melanomA Patients… NCT05180942 | Active, Not Recruiting | Completion pushed from Jun 2026 to Dec 2026 | 2026-10-09 |
| A Study of TRK-950 in Patients With Advanced Solid Tumors NCT05423262 | Recruiting | Completion pushed from Dec 2027 to Mar 31, 2028 | 2026-10-09 |
| Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) NCT03340129 | Recruiting | Primary completion pushed from Aug 2026 to Dec 2026 | 2026-10-09 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple… NCT04572451 | Active, Not Recruiting | Completion pushed from May 31, 2027 to Aug 5, 2027 | 2026-08-21 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.